Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ePoster Display

42P - Analysis of canonical uveal melanoma aberrations in murine uveal melanocytes

Date

16 Sep 2021

Session

ePoster Display

Topics

Cancer Biology

Tumour Site

Presenters

Yoseph Sayegh

Citation

Annals of Oncology (2021) 32 (suppl_5): S361-S375. 10.1016/annonc/annonc684

Authors

Y. Sayegh, J.N. Kuznetsoff, S. Kurtenbach, J.J. Dollar, J.W. Harbour

Author affiliations

  • Ophthalmology, University of Miami, Bascom Palmer Eye Institute/Sylvester Comprehensive Cancer Center, 33136 - Miami/US

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 42P

Background

Uveal melanoma (UM) is the most common cancer of the eye. Previous research has identified three key driver mutations in UM tumorigenesis: 1) gain of function Gq signaling pathway mutations, 2) BAP1 loss of function mutations, and 3) aberrant expression of PRAME. However, the combined impact of these aberrations is not known. The purpose of this study was to characterize the phenotype of uveal melanocytes harboring one or more of these aberrations.

Methods

Uveal melanocytes were isolated from adult and neonatal murine choroid and were genetically engineered to express one or more of the three canonical aberrations. Phenotypic and transcriptional assays were performed to assess phenotypic changes.

Results

The stepwise addition of these aberrations resulted in progressive deregulation of transcriptome, morphology, and growth properties resembling findings in human uveal melanoma.

Conclusions

This unique genetically engineered mouse uveal melanocyte model will be invaluable for understanding how the progressive genetic evolution of human uveal melanoma results in increased malignant propensity.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

J. William Harbour.

Funding

Melanoma Research Foundation.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.